Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Madaras-Kelly, K. J.
Right arrow Articles by Thompson, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Madaras-Kelly, K. J.
Right arrow Articles by Thompson, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2002) 50, 211-218
© 2002 The British Society for Antimicrobial Chemotherapy

Pharmacodynamic characterization of efflux and topoisomerase IV-mediated fluoroquinolone resistance in Streptococcus pneumoniae

Karl J. Madaras-Kelly1,2,*, Christopher Daniels2, Marissa Hegbloom1,2 and Michelle Thompson1,2

1 Veterans Affairs Medical Center, 500 W. Fort Street, Boise, ID 83702; 2 College of Pharmacy, Idaho State University, Pocatello, ID, USA

Received 6 August 2001; returned 4 March 2002; revised 15 April 2002; accepted 29 April 2002

Objectives: Most in vitro investigations of fluoroquinolone resistance involving Streptococcus pneumoniae have described genotypic changes in quinolone resistance-determining regions (QRDRs) that occur as the result of exposure to fluoroquinolones obtained with static antimicrobial concentrations. The objectives of this study were to determine whether differences exist between moxifloxacin, sparfloxacin and levofloxacin antimicrobial effect (AME) and their ability to select out stepwise mutations with wild-type, efflux-expressing and parC-mediated fluoroquinolone resistance while simulating the in vivo dosing and pharmacokinetics of the respective agents.

Methods: A one-compartment pharmacodynamic model simulated fluoroquinolone dosing regimens. Duplicate 24 h experiments were carried out in Mueller–Hinton broth with 3% horse blood at 1 x 108 cfu/mL. Reserpine (10 mg/L) was added to select experiments conducted with efflux-expressing strains. AME was expressed as the area under the time–concentration kill curve (AUEC24). Strains expressing increased MIC post-time–concentration kill curve (TCKC) were evaluated for changes in QRDR.

Results: Moxifloxacin exhibited a greater AME against all isolates. Efflux was generally associated with partial loss of AME for all fluoroquinolones, and levofloxacin retained no AME against parC-expressing S. pneumoniae. Increased fluoroquinolone MIC post-TCKC was more common with efflux expression. The addition of reserpine was associated with enhanced AME for levofloxacin and moxifloxacin, but was not associated with altered resistance selection. Isolates recovered post-TCKC from experiments involving efflux- or parC mutation-containing isolates generally exhibited a more than four-fold increase in MIC, which was associated with commonly reported substitutions in both parC and gyrA.

Conclusion: The results of this study generally indicate that resistance selection under pharmacodynamic conditions is similar to results reported with static fluoroquinolone concentrations. While moxifloxacin AME was greater than levofloxacin and sparfloxacin, the overall selection of resistant isolates did not differ.

* Corresponding author. Tel: +1-208-422-1146; Fax: +1-208-422-1147; E-mail: kmk{at}otc.isu.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Antimicrob. Agents Chemother.Home page
E. Marrer, K. Schad, A. T. Satoh, M. G. P. Page, M. M. Johnson, and L. J. V. Piddock
Involvement of the Putative ATP-Dependent Efflux Proteins PatA and PatB in Fluoroquinolone Resistance of a Multidrug-Resistant Mutant of Streptococcus pneumoniae
Antimicrob. Agents Chemother., February 1, 2006; 50(2): 685 - 693.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
E. Marrer, A. T. Satoh, M. M. Johnson, L. J. V. Piddock, and M. G. P. Page
Global Transcriptome Analysis of the Responses of a Fluoroquinolone-Resistant Streptococcus pneumoniae Mutant and Its Parent to Ciprofloxacin
Antimicrob. Agents Chemother., January 1, 2006; 50(1): 269 - 278.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
S. Malhotra-Kumar, C. Lammens, S. Chapelle, C. Mallentjer, J. Weyler, and H. Goossens
Clonal spread of fluoroquinolone non-susceptible Streptococcus pyogenes
J. Antimicrob. Chemother., March 1, 2005; 55(3): 320 - 325.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
D. Croisier, M. Etienne, E. Bergoin, P.-E. Charles, C. Lequeu, L. Piroth, H. Portier, and P. Chavanet
Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy
Antimicrob. Agents Chemother., May 1, 2004; 48(5): 1699 - 1707.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
N. R. Florea, P. R. Tessier, C. Zhang, C. H. Nightingale, and D. P. Nicolau
Pharmacodynamics of Moxifloxacin and Levofloxacin at Simulated Epithelial Lining Fluid Drug Concentrations against Streptococcus pneumoniae
Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1215 - 1221.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.